AU2018298849B2 - A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (MSI) cancers - Google Patents

A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (MSI) cancers Download PDF

Info

Publication number
AU2018298849B2
AU2018298849B2 AU2018298849A AU2018298849A AU2018298849B2 AU 2018298849 B2 AU2018298849 B2 AU 2018298849B2 AU 2018298849 A AU2018298849 A AU 2018298849A AU 2018298849 A AU2018298849 A AU 2018298849A AU 2018298849 B2 AU2018298849 B2 AU 2018298849B2
Authority
AU
Australia
Prior art keywords
cancer
leu
ser
arg
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018298849A
Other languages
English (en)
Other versions
AU2018298849A1 (en
Inventor
Armin Lahm
Guido LEONI
Alfredo Nicosia
Elisa Scarselli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nouscom AG
Original Assignee
Nouscom AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nouscom AG filed Critical Nouscom AG
Publication of AU2018298849A1 publication Critical patent/AU2018298849A1/en
Application granted granted Critical
Publication of AU2018298849B2 publication Critical patent/AU2018298849B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018298849A 2017-07-12 2018-07-12 A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (MSI) cancers Active AU2018298849B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17181026 2017-07-12
EP17181026.0 2017-07-12
PCT/EP2018/069032 WO2019012082A1 (en) 2017-07-12 2018-07-12 UNIVERSAL VACCINE BASED ON SHARED TUMOR NEO-ANTIGENS FOR THE PREVENTION AND TREATMENT OF MICRO-SATELLITE INSTABILITY CANCER (MSI)

Publications (2)

Publication Number Publication Date
AU2018298849A1 AU2018298849A1 (en) 2020-01-02
AU2018298849B2 true AU2018298849B2 (en) 2022-07-14

Family

ID=59366234

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018298849A Active AU2018298849B2 (en) 2017-07-12 2018-07-12 A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (MSI) cancers

Country Status (19)

Country Link
US (1) US11578109B2 (OSRAM)
EP (1) EP3652606B1 (OSRAM)
JP (1) JP7274223B2 (OSRAM)
KR (1) KR102709778B1 (OSRAM)
CN (1) CN111328420B (OSRAM)
AU (1) AU2018298849B2 (OSRAM)
BR (1) BR112020000590A2 (OSRAM)
CA (1) CA3069047A1 (OSRAM)
DK (1) DK3652606T5 (OSRAM)
ES (1) ES2940087T3 (OSRAM)
FI (1) FI3652606T3 (OSRAM)
HU (1) HUE061840T2 (OSRAM)
IL (1) IL271966B2 (OSRAM)
MX (1) MX2020000413A (OSRAM)
NZ (1) NZ759940A (OSRAM)
PL (1) PL3652606T3 (OSRAM)
PT (1) PT3652606T (OSRAM)
SG (1) SG11202000250PA (OSRAM)
WO (1) WO2019012082A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020022897A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
EP3827265A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Cancer vaccines for kidney cancer
IL321692A (en) 2018-07-26 2025-08-01 Curevac Netherlands B V Cancer vaccines for colorectal cancer
US20210162032A1 (en) 2018-07-26 2021-06-03 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
WO2020022901A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for uterine cancer
US20210252123A1 (en) 2018-07-26 2021-08-19 Frame Pharmaceuticals B.V. ARID1A, CDKN2A, KMT2B, KMT2D, TP53 and PTEN VACCINES FOR CANCER
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
WO2020163802A1 (en) * 2019-02-07 2020-08-13 Arizona Board Of Regents On Behalf Of Arizona State University Cancer specific frameshift vaccines
CA3161800A1 (en) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
US20230212243A1 (en) * 2020-05-12 2023-07-06 Institut Curie Neoantigenic Epitopes Associated with SF3B1 Mutations
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
US20240218019A1 (en) * 2021-04-06 2024-07-04 Board Of Regents, The University Of Texas System Methods and compositions comprising mhc class i peptides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187508A2 (en) * 2015-05-20 2016-11-24 The Broad Institute Inc. Shared neoantigens

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
US8053552B2 (en) * 2002-04-18 2011-11-08 Mtm Laboratories, Ag Neopeptides and methods useful for detection and treatment of cancer
US20060160090A1 (en) * 2003-04-11 2006-07-20 Macina Robert A Composition splice variants and methods relating to cancer specific genes and proteins
CN1824325A (zh) * 2005-12-16 2006-08-30 武汉大学 人乳头病毒dna嵌合疫苗及制备方法和应用
KR101454287B1 (ko) * 2006-10-17 2014-11-04 온코세라피 사이언스 가부시키가이샤 Ｍｐｈｏｓｐｈ1 또는 ｄｅｐｄｃ1 폴리펩티드를 발현하는 암에 대한 펩티드 백신
TW201102081A (en) * 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
AU2010252939B2 (en) 2009-05-29 2014-06-26 Morphosys Ag A collection and methods for its use
MX2012011668A (es) * 2010-04-09 2012-12-17 Oncotherapy Science Inc Peptidos cdca5 y vacunas que incluyen los mismos.
AU2012230259B2 (en) * 2011-03-24 2017-04-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Dominant negative HSP110 mutant and its use in prognosing and treating cancers
BR112014001363B1 (pt) * 2011-08-12 2021-06-01 Oncotherapy Science, Inc. Composições para indução de um linfócito t citotóxico (ctl), para indução de uma célula apresentadora de antígeno (apc) tendo capacidade de indução de ctl, composição farmacêutica, métodos in vitro para indução de apc e de ctl, usos de peptídeos e vetor
JP5890769B2 (ja) * 2012-12-13 2016-03-22 ループレヒト−カルルス・ウニヴェルジテート・ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ がんの予防及び治療のためのｍｓｉ特異的なフレームシフトペプチド（ｆｓｐ）
WO2014090265A1 (en) * 2012-12-13 2014-06-19 Ruprecht-Karls-Universität Heidelberg Msi-specific frameshift peptides (fsp) for prevention and treatment of cancer
US9205140B2 (en) * 2012-12-13 2015-12-08 Ruprecht-Karls-Universität MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer
WO2014099979A2 (en) * 2012-12-17 2014-06-26 Virginia Tech Intellectual Properties, Inc. Methods and compositions for identifying global microsatellite instability and for characterizing informative microsatellite loci
US11098367B2 (en) * 2014-01-27 2021-08-24 Yale University Methods of identifying patients responsive to immunotherapeutic strategies
CN106350578A (zh) * 2015-07-13 2017-01-25 中国人民解放军第二军医大学 Ny-eso-1在微卫星不稳定性肠癌的诊断和治疗中的应用
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187508A2 (en) * 2015-05-20 2016-11-24 The Broad Institute Inc. Shared neoantigens

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SCHWITALLE YVETTE; LINNEBACHER MICHAEL; RIPBERGER EVA; GEBERT JOHANNES; VON KNEBEL DOEBERITZ MAGNUS: "Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells.", CANCER IMMUNITY, ACADEMY OF CANCER IMMUNOLOGY, CH, vol. 4, no. 1, 25 November 2004 (2004-11-25), CH , pages 1 - 10, XP009502707, ISSN: 1424-9634 *
SHEN LUHUI ET AL: vol. 73, no. 8, Suppl. 1, April 2013, & 104TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER RESEARCH APRIL, 2013, Retrieved from the Internet *
WOERNER S M ET AL: EUROPEAN J OF CANCER, vol. 93, October 2001 (2001-10-01), & 11TH EUROPEAN CANCER CONFERENCE; OCT, 2001, pages 12 - 19, *

Also Published As

Publication number Publication date
CA3069047A1 (en) 2019-01-17
KR20200029443A (ko) 2020-03-18
WO2019012082A9 (en) 2019-05-02
EP3652606A1 (en) 2020-05-20
PT3652606T (pt) 2023-03-16
CN111328420B (zh) 2023-07-25
WO2019012082A1 (en) 2019-01-17
MX2020000413A (es) 2020-09-28
DK3652606T5 (da) 2024-08-26
AU2018298849A1 (en) 2020-01-02
FI3652606T3 (fi) 2023-03-16
CN111328420A (zh) 2020-06-23
SG11202000250PA (en) 2020-02-27
IL271966A (en) 2020-02-27
HUE061840T2 (hu) 2023-08-28
JP7274223B2 (ja) 2023-05-16
DK3652606T3 (da) 2023-03-13
ES2940087T3 (es) 2023-05-03
RU2019144505A (ru) 2021-08-12
BR112020000590A2 (pt) 2020-07-14
IL271966B1 (en) 2024-09-01
JP2020532288A (ja) 2020-11-12
NZ759940A (en) 2023-07-28
PL3652606T3 (pl) 2023-04-24
EP3652606B1 (en) 2023-01-11
US11578109B2 (en) 2023-02-14
US20200222519A1 (en) 2020-07-16
RU2019144505A3 (OSRAM) 2021-08-12
IL271966B2 (en) 2025-01-01
KR102709778B1 (ko) 2024-09-26

Similar Documents

Publication Publication Date Title
AU2018298849B2 (en) A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (MSI) cancers
AU2020203837B2 (en) Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
AU2020204520B2 (en) Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
AU2020202369B2 (en) Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
AU2023251441A1 (en) RNA containing composition for treatment of tumor diseases
AU2017234120B2 (en) Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
AU2017235661B2 (en) Oligonucleotide probes and uses thereof
AU2023214237A1 (en) Modified polynucleotides for the production of biologics and proteins associated with human disease
AU2016381496B2 (en) Plant traits conferred by isolated polynucleotides and polypeptides
KR102719587B1 (ko) 아데노-관련 바이러스 생산을 위한 포유동물 세포
KR102630357B1 (ko) 단백질 발현이 어려운 다중-부위 ssi 세포
TW202321448A (zh) 利用重組環狀rna改善蛋白質轉譯的組合物及方法
AU2021203894A1 (en) Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
JP2003088388A (ja) 新規な全長ｃＤＮＡ
JP2003135075A (ja) 新規な全長ｃＤＮＡ
KR20150129847A (ko) 융합 단백질 및 이들의 방법
WO2000058473A2 (en) Nucleic acids including open reading frames encoding polypeptides; 'orfx'
AU2019316556B2 (en) Methods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing
AU2017289886A1 (en) Engineered parasites for delivering protein to the central nervous system (CNS)
KR20220054401A (ko) 감염의 숙주 rna 바이오마커의 신속한 조기-검출 및 인간의 covid-19 코로나바이러스 감염의 조기 식별을 위한 시스템, 방법 및 조성물
JP2003304888A (ja) 化合物の毒性予測のための方法
AU2017336160B2 (en) Screening methods using olfactory receptors and novel compounds identified using the same
AU2016295122A1 (en) Genetic testing for predicting resistance of pseudomonas species against antimicrobial agents
JP2003235573A (ja) 糖尿病性腎症マーカーおよびその利用
KR101978399B1 (ko) 자궁내막증에 대한 진단 마커로서의 돌연변이 유전자 및 이의 용도

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)